A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer.

Trial Profile

A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Doxorubicin (Primary) ; Epirubicin (Primary) ; Cyclophosphamide; Docetaxel
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NATT
  • Most Recent Events

    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 29 Sep 2012 Primary endpoint 'Complete-pathological-response-rate' has not been met.
    • 10 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top